Novo Nordisk A/S Class B EBIT

The latest EBIT for NONOF is $160B as of June 2026. That compares with $150B in the prior-year period — up 5.0% year over year. That is above the Healthcare sector average of $23B. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Over the past year, NONOF's EBIT moved from $150B to $160B — a 5.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S Class B's operating scale or balance-sheet position.

Against Healthcare companies, NONOF currently prints $160B for EBIT, while the sector average sits near $23B. That is roughly 590.5% above the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.

A EBIT figure of $160B for NONOF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting NONOF's EBIT ($160B), review year-over-year change from $150B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.